2 results match your criteria: "Hospital do Espirito Santo-Evora E. P. E.[Affiliation]"
Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here.
Heart Fail Rev
November 2022
Serviço de Medicina, Hospital do Espírito Santo-Évora E.P.E, Évora, Portugal.
Heart failure with a preserved ejection fraction (HFpEF), previously known as diastolic heart failure, was first recognized more than 50 years ago. In spite of all the advances in the knowledge of HFpEF, important questions remain, namely the fact that no therapy has been shown to improve outcomes in these patients. The EMPEROR-Preserved Trial, a trial on the use of empagliflozin on patients with HFpEF, published in October 2021, was the first trial to ever show a change in outcomes in these patients.
View Article and Find Full Text PDFTherapeutic implications of transesophageal echocardiography after transthoracic echocardiography on acute stroke patients.
Vasc Health Risk Manag
September 2008
Laboratorio de Ultrasonografia Cardiaca e Neurovascular, Hospital do Espirito Santo-Evora E. P. E., Portugal.
Background: The role of transesophageal echocardiography (TEE) in the evaluation of acute stroke patients is still ill-defined. We conducted a prospective observational study to find the prevalence of TEE findings that indicate anticoagulation as beneficial, in acute ischemic stroke patients without indication for anticoagulation based on clinical, electrocardiographic and transthoracic echocardiography (TTE) findings.
Methods: We prospectively studied all patients referred to our laboratory for TTE and TEE.